Janux Therapeutics JANX

Dr. David Campbell, PhD is our founder and has served as President and Chief Executive Officer and as a member of our Board of Directors since our inception in June 2017. Prior to founding Janux, Dr. Campbell was an Entrepreneur in Residence at Avalon Ventures from March 2013 to December 2019. Dr. Campbell served as the Chief Scientific Officer for Sitari Pharmaceuticals, Inc. from November 2013 through August 2019 and for Iron Horse Therapeutics, Inc. from November 2015 to June 2019. Dr. Campbell served as the President and Chief Executive Officer of Enlibirum from November 2015 through December 2017. Dr. Campbell received a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Organic Chemistry from Cornell University, and received post-doctoral training under then University of California, Berkeley professor Dr. Peter Schultz.

Ms. Janeen Noel Doyle has served as our Chief Corporate and Business Development Officer since May 2025. Previously, Ms. Doyle served as Senior Partner and Senior Vice President of Corporate Partnerships and Program Development at Flagship Pioneering, Inc. (Flagship) from June 2024 to May 2025, where she was responsible for strategy and execution of collaborations between Flagship's portfolio companies and global pharmaceutical and technology partners. From 2019 to June 2024, Ms. Doyle held multiple positions at Bristol-Myers Squibb, including Senior Vice President of Strategy of Business Development and Vice President of Business Development and Global Alliances. From 2009 to 2019, Ms. Doyle held multiple positions at Celgene Corporation, a global biopharmaceutical company (acquired by Briston-Myers Squibb), including Executive Director of Business Development & Global Alliances and Director of Global Program Leadership. Previous to that, she held roles in clinical science and operations. Ms. Doyle received a B.S. in Biology from Moravian University and a M.B.A. from the University of Scranton.

Dr. Thomas DiRaimondo, PhD is one of our co-founders and has served as our Chief Scientific Officer since January 2024 and had previously served as our Executive Director, Head of Research and Development from January 2023 through December 2023, Senior Director of Therapeutics Discovery from January 2022 through December 2022, and Director of Research from January 2018 through December 2021. Previously, Dr. DiRaimondo served at Sitari Pharma, Inc., which he co-founded, as Director of Research from January 2020, and Principal Scientist from December 2013. Dr. DiRaimondo received a B.S.E in chemical engineering and M.Eng in pharmaceutical engineering from the University of Michigan, Ann Arbor as well as a M.S. and Ph.D. in chemical engineering from Stanford University.

Dr. Ronald W. Barrett, PhD has served as a member of our Board of Directors since September 2021. Dr. Barrett also serves as a member of the board of directors of Quadriga Biosciences, a private oncology company. Dr. Barrett served as Executive Chairman of Medikine, Inc., a biopharmaceutical company, from January 2023 to July 2023 and previously served as its Chief Executive Officer and Chairman of the board of directors from June 2017 until January 2023, and as its Executive Chair from December 2016 to June 2017. Dr. Barrett was a founder of XenoPort, Inc. (XenoPort), a biopharmaceutical company, and served as its Chief Executive Officer from 2001 to October 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to October 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University.

Ms. Vickie L. Capps has served as a member of our Board of Directors since March 2021. Ms. Capps has also served as a member of the board of directors of Orthofix Medical, Inc., a public medical device company, since March 2025, and is a member of its audit committee and its compensation committee. In addition, Ms. Capps serves as a member of the boards of directors of Enable Injections, Inc. and Breg, Inc., both private medical device companies, a member of the senior advisory board of Consonance Capital Partners, a healthcare investment firm, and is also a member of the board of directors of the San Diego State University Research Foundation and a member of its audit committee and its finance and investment committee. Ms. Capps previously served on the board of directors of Amedisys, Inc., a public healthcare service provider, from October 2019 until the closing of its acquisition by UnitedHealth Group in August 2025, of NuVasive, Inc., a public medical device company, from June 2015 until the closing of its merger with Globus Medical, Inc. in September 2023, of Otonomy, Inc., a public biotechnology company, from March 2014 until February 2023, of Silverback Therapeutics, Inc., a public biotechnology company, from June 2020 until the closing of its merger with ARS Pharmaceuticals, Inc. in November 2022, of Synthorx, Inc., a public biotechnology company, from April 2018 until its sale to Sanofi S.A. (Sanofi) in January 2020, and of Connecture, Inc., a healthcare IT company, from October 2014 to April 2018. Ms. Capps has also previously served on the boards of directors of several other public and private companies, including OmniGuide Holdings, Inc., RF Surgical Systems, Inc., Eagle Rx, Inc. and SenoRx, Inc. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc., a medical device company. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a California Certified Public Accountant and was recognized as a CFO of the Year Honoree by the San Diego Business Journal in 2009 and 2010 and as a Director of the Year Honoree by the Corporate Directors Forum in 2022. Ms. Capps received a B.A. in Business Administration/Accounting from San Diego State University.

Dr. Jake Simson, PhD has served as a member of our Board of Directors since March 2021. Dr. Simson has served as a partner at RA Capital Management, L.P. (RA Capital) since December 2020. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital from July 2013 to December 2020. Dr. Simson also serves as a member of the boards of directors of Tyra Biosciences, Inc., Bicara Therapeutics, Inc., and Septerna Inc., each a public biotechnology company. He also serves on the boards of directors of Convergent Therapeutics, Inc., Outpace Bio, Inc., Parabilis Medicines, Inc. and Vivace Therapeutics, Inc., each a private biotechnology company. Dr. Simson received an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and a Ph.D. in Biomedical Engineering from the Johns Hopkins University.

Ms. Alana B. McNulty has served as a member of our Board of Directors since September 2021. Ms. McNulty served as Chief Business Officer of Effector Therapeutics, Inc. (Effector) from July 2019 to July 2022. Previously, Ms. McNulty served as Chief Financial Officer of Effector from July 2012 until December 2020 (in a consulting capacity until October 2015). Ms. McNulty served as Chief Financial Officer of Lumena Pharmaceuticals Inc. from July 2012 until its acquisition by Shire plc in November 2014, and as Chief Financial Officer of Excaliard Pharmaceuticals, Inc. from March 2011 through its acquisition by Pfizer Inc. in November 2011. Prior to that, Ms. McNulty was acting Chief Financial Officer at BrainCells, Inc. from 2004 until 2011 and Chief Financial Officer of Elitra Pharmaceuticals Inc. from 1998 to 2003. Prior to that, Ms. McNulty was head of Corporate Development and a General Manager of a business unit at Advanced Tissue Sciences. Ms. McNulty has served on the board of directors of Lipidio Pharmaceuticals, a biopharmaceutical company, since February 2023. Ms. McNulty received a B.A. in Biology from the University of California, Santa Barbara and an M.B.A. from the Anderson School of Business at the University of California, Los Angeles.

Mr. Winston Kung, M.B.A. has served as a member of our Board of Directors since September 2022. Mr. Kung has served as the Chief Financial Officer and Treasurer of ArriVent BioPharma, Inc., a biopharmaceutical company, since January 2024. From December 2017 to January 2024, Mr. Kung served as the Chief Operating Officer and Chief Financial Officer of PMV Pharmaceuticals, Inc., a public precision oncology company. From April 2013 to November 2017, Mr. Kung held multiple positions at Celgene Corporation, a global biopharmaceutical company (acquired by Bristol-Myers Squibb), including Vice President of Business Development and Global Alliances, and Chief Business Officer at Celgene Cellular Therapeutics (a wholly-owned subsidiary of Celgene Corporation). Prior to Celgene, Mr. Kung worked at Citigroup from June 2010 to April 2013 in its Global Healthcare Investment Banking group and at Lehman Brothers (which was subsequently acquired by Barclays) from May 2007 to June 2010 in its Global Mergers and Acquisition Group. From August 2004 to May 2007, Mr. Kung worked at Amgen, a public biopharmaceutical company, as a co-founder of the Alliance Management group, and served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung also worked at Genentech, a biotechnology company (acquired by Roche Holding AG), from November 1999 to September 2002 as part of the Business and Corporate Development group. Mr. Kung has served on the board of directors of Corbus Pharmaceuticals, a public biotechnology company, since August 2024. Mr. Kung received a B.A. in Biology and International Relations from Brown University and a M.B.A. from Harvard Business School.

Ms. Natasha A. Hernday has served as a member of our Board of Directors since July 2024. Ms. Hernday brings extensive experience in business development, corporate strategy and alliance management, having served as Chief Business Officer and a member of the Executive Committee at Seagen Inc. (Seagen) from December 2022 until its acquisition by Pfizer in December 2023, and previously as Executive Vice President, Corporate Development from October 2020 until December 2022. Ms. Hernday joined Seagen in 2011 where she built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. Prior to her role at Seagen, Ms. Hernday spent 16 years at Amgen, Inc. (Amgen), where she began her career in discovery research, then held various leadership positions in corporate development and corporate strategy, including as Director, Mergers & Acquisitions and as Director, Out-Partnering, playing a key role in numerous high-value transactions. Ms. Hernday has served on the boards of directors of Xoma Corp. since June 2019 and Firefly Biologics, Inc. since September 2024 and on the Knight Campus External Advisory Board for the University of Oregon. Ms. Hernday previously served on the boards of directors of Alpine Immune Sciences, Inc., from December 2020 until its acquisition by Vertex Pharmaceuticals Incorporated in May 2024, and PDL BioPharma, Inc., from June 2019 until January 2021. Ms. Hernday received a B.A. in microbiology from the University of California, Santa Barbara and an M.B.A. from Pepperdine University.

Dr. Sheila Gujrathi, M.D. has served as a member of our Board of Directors since March 2021. Dr. Gujrathi also serves as the Executive Chair of the board of directors of Ventyx Biosciences, Inc., a public biopharmaceutical company and the Executive Chair of private biopharmaceutical companies, Lila Biologics, Inc. and Generian Pharmaceuticals, Inc. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a biopharmaceutical company, from June 2020 to January 2025, and on the board of directors of Turning Point Therapeutics, Inc., a public biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors from April 2019 to March 2021. Dr. Gujrathi also previously served on the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen in April 2021) from December 2015 to June 2019 and Ambrx, Inc. from February 2014 until its acquisition in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a public biopharmaceutical company, and served as President and Chief Executive Officer from July 2018 to November 2020 and as President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi joined Receptos, Inc. from Bristol-Myers Squibb Company (Bristol-Meyers Squibb), where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc. (Genentech), where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and an M.D. from Northwestern University in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.

Mr. William Go has served as our Chief Medical Officer since January 2026. Previously, Dr. Go served as Chief Medical Officer at A2 Biotherapeutics, Inc. (A2 Bio), a private biotherapeutics company, from 2019 to June 2025, where he led development of logic-gated CAR T-cell therapies for solid tumors. During his tenure, A2 Bio initiated three Phase 1 clinical trials across multiple solid tumor indications. Prior to A2 Bio, Dr. Go held multiple positions at Kite Pharma, Inc. (Kite), a biotechnology company (acquired by Gilead Sciences, Inc. (Gilead)) from 2014 to 2019, including Vice President of Clinical Development and Senior Medical Director where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA, the first CAR T-cell therapy approved for large B-cell lymphoma. Following Kite's acquisition by Gilead, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma. From 2011 to 2014, Dr. Go held various positions at Amgen, a public biopharmaceutical company, in the hematology/oncology department. Dr. Go completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes. Dr. Go received a B.A. in Biology from Carleton College and an M.D., Medicine, and Ph.D., in Biomedical Sciences with a focus in Immunology from UC San Diego School of Medicine.

Mr. Charles M. Winter has served as our Chief Medical Officer since January 2026. Previously, Dr. Go served as Chief Medical Officer at A2 Biotherapeutics, Inc. (A2 Bio), a private biotherapeutics company, from 2019 to June 2025, where he led development of logic-gated CAR T-cell therapies for solid tumors. During his tenure, A2 Bio initiated three Phase 1 clinical trials across multiple solid tumor indications. Prior to A2 Bio, Dr. Go held multiple positions at Kite Pharma, Inc. (Kite), a biotechnology company (acquired by Gilead Sciences, Inc. (Gilead)) from 2014 to 2019, including Vice President of Clinical Development and Senior Medical Director where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA, the first CAR T-cell therapy approved for large B-cell lymphoma. Following Kite's acquisition by Gilead, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma. From 2011 to 2014, Dr. Go held various positions at Amgen, a public biopharmaceutical company, in the hematology/oncology department. Dr. Go completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes. Dr. Go received a B.A. in Biology from Carleton College and an M.D., Medicine, and Ph.D., in Biomedical Sciences with a focus in Immunology from UC San Diego School of Medicine.

Maria joined Janux in March 2021 prior to the company's IPO. In her current role as Vice President, Accounting, she leads the accounting function including overseeing the company's financial reporting, technical accounting and compliance with Sarbanes-Oxley. Prior to joining Janux, Maria worked in various roles of increasing responsibility for over 9 years at Ernst & Young, LLP, most recently as Assurance Senior Manager. During her tenure at E&Y, Maria led financial statement audits, assisted clients with first year SOX 404(b) implementations as well as SEC filings and registrations, including initial public offerings, secondary offerings and debt offerings. Primarily serving clients in the life science sector while at E&Y, her clients ranged in size from venture capital backed start-up companies to multi-billion-dollar market cap SEC registrants. Maria holds a Bachelor of Business Administration and Master's degree in Accounting from the University of Georgia. She is a Certified Public Accountant in the State of California. Ms. Maria Dobek is on temporary leave from the Company, effective as of February 25, 2026.